Beacon Equity Research announces the release of Stock Alerts covering Monday’s market movers: Advaxis Inc. (OTCBB: ADXS), Keryx Biopharmaceuticals Inc. (Nasdaq: KERX), General Motors Corp. (NYSE: GM) and Cell Therapeutics Inc. (Nasdaq: CTIC).
The stock alert features the most recent headlines, share price and technical analysis for each covered company. The full alert, as well as other articles, market research and more can be found at BeaconEquity.com
In the Stock Alert, the author highlights Advaxis obtaining a U.S. Patent and Trademark Office approval for Act-A Protein Patent-Pending Rights:
“Advaxis Inc. (OTCBB: ADXS) shares soared 18.54% this morning, trading at 17 cents. Advaxis engages in the research and development of new cancer-fighting techniques primarily in the United States. The company recently announced it obtained a U.S. Patent and Trademark Office approval on its patent-application Compositions and Methods for Enhancing the Immunogenicity of Antigens, which covers the use of Listeria monocytogenes (Lm) protein ActA and fragments of this protein for use in the creation of antigen fusion proteins. … According to its release, the ActA protein has been found to possess immuno-adjuvant properties. The company's proprietary technology is based, in part, upon bioengineered Lm that secretes antigen-adjuvant fusion proteins.”
The Stock Alert author also featured Keryx Biopharmaceuticals’ phase 2 data of KRX-0401 for advanced metastatic renal cell cancer treatment:
“Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) shares skyrocketed 91.43% to $1.34 in today’s early trading. Keryx Biopharmaceuticals focuses on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. … New York-based Keryx Biopharmaceuticals recently announced phase 2 data of KRX-0401 for advanced metastatic renal cell cancer treatment. According to its report, KRX-0401 is an oral anti-cancer agent that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. … The study enrolled a total of 50 patients, of which 46 patients were evaluable for response. Evaluable patients were defined as those who had greater than seven days of treatment.”
Investors can view all of the Stock Alerts and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
BeaconEquity.com is a Web site wholly owned by BlueWave Advisors, LLC. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BlueWave Advisors LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
